Apyx Medical CorpNASDAQ:APYX
- LAST PRICE1.4800
- TODAY'S CHANGE (%)-0.0200 (-1.3333%)
- Bid / Lots1.4500/ 3
- Ask / Lots1.5300/ 8
- Open / Previous Close1.4800 / 1.5000
- Day Range
- 52 Week Range
- Volume68,488
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | APYX |
|---|---|---|
| 09:32 ET | 1640 | 1.5 |
| 09:34 ET | 1928 | 1.47 |
| 09:36 ET | 400 | 1.46 |
| 09:39 ET | 31147 | 1.48 |
| 09:41 ET | 867 | 1.46 |
| 09:56 ET | 4000 | 1.4611 |
| 10:17 ET | 100 | 1.48 |
| 10:19 ET | 952 | 1.465 |
| 10:24 ET | 100 | 1.475 |
| 10:32 ET | 100 | 1.475 |
| 10:35 ET | 100 | 1.46 |
| 10:51 ET | 100 | 1.45 |
| 11:13 ET | 200 | 1.47 |
| 11:15 ET | 900 | 1.47 |
| 11:27 ET | 600 | 1.47 |
| 11:33 ET | 100 | 1.46 |
| 11:42 ET | 100 | 1.46 |
| 11:49 ET | 100 | 1.46 |
| 11:58 ET | 100 | 1.47 |
| 12:05 ET | 100 | 1.47 |
| 12:07 ET | 1442 | 1.48 |
| 12:12 ET | 100 | 1.47 |
| 12:25 ET | 2900 | 1.4401 |
| 12:30 ET | 100 | 1.45 |
| 12:45 ET | 700 | 1.45 |
| 12:48 ET | 100 | 1.45 |
| 12:56 ET | 100 | 1.45 |
| 01:01 ET | 250 | 1.44 |
| 01:06 ET | 100 | 1.45 |
| 01:14 ET | 100 | 1.44 |
| 01:21 ET | 100 | 1.44 |
| 02:02 ET | 6403 | 1.4401 |
| 02:06 ET | 197 | 1.44 |
| 02:09 ET | 100 | 1.44 |
| 02:15 ET | 691 | 1.44 |
| 02:22 ET | 250 | 1.44 |
| 02:29 ET | 100 | 1.45 |
| 02:36 ET | 100 | 1.45 |
| 02:42 ET | 100 | 1.45 |
| 02:47 ET | 100 | 1.45 |
| 02:56 ET | 100 | 1.45 |
| 03:02 ET | 100 | 1.45 |
| 03:07 ET | 100 | 1.45 |
| 03:12 ET | 100 | 1.45 |
| 03:18 ET | 100 | 1.45 |
| 03:23 ET | 100 | 1.45 |
| 03:27 ET | 900 | 1.45 |
| 03:32 ET | 200 | 1.45 |
| 03:36 ET | 100 | 1.45 |
| 03:39 ET | 100 | 1.45 |
| 03:41 ET | 140 | 1.4511 |
| 03:43 ET | 1100 | 1.46 |
| 03:52 ET | 100 | 1.46 |
| 03:56 ET | 200 | 1.46 |
| 03:57 ET | 100 | 1.46 |
| 03:59 ET | 2938 | 1.48 |
Today
Apyx Medical Corporation to Release First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024, from 15 hours ago by Dow Jones
15 hours ago by Dow JonesPress Release: Apyx Medical Corporation to Release First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024, from 15 hours ago by Dow Jones
15 hours ago by Dow Jones
Apr 11, 2024
Apyx Medical Corporation Showcases New Data and Treatment Insights at the Renuvion(R) Users' Summit, from 7:30AM ET on Thursday Apr 11, 2024 by Dow Jones
7:30AM ET on Thursday Apr 11, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Apyx Medical Corp | 52.0M | -2.7x | --- |
DIH Holding US Inc | 53.9M | -32.1x | --- |
Pro-Dex Inc | 65.0M | 13.3x | +37.17% |
Alpha Pro Tech Ltd | 68.5M | 17.3x | +6.36% |
Retractable Technologies Inc | 32.3M | -4.4x | --- |
Alpha Teknova Inc | 69.8M | -1.5x | --- |
Company Information
Apyx Medical Corporation is an advanced energy technology company. The Company's segments include Advanced Energy and OEM. The Advanced Energy segment's product portfolio consists of its Helium Plasma Technology that is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It is focused on the cosmetic surgery market where Renuvion offers plastic surgeons, facial plastic surgeons and cosmetic physicians an ability to provide controlled heat to the tissue to achieve their desired results. Its product lines consist of a multifunction generator, a handpiece and a supply of helium gas. The OEM segment leverages its expertise in the design, development and manufacturing of electrosurgical equipment and medical devices by producing generators, medical devices and related accessories for medical device manufacturers through original equipment manufacturing agreements, as well as start-up companies with the need for its energy-based designs.
Contact Information
- Headquarters
- 5115 Ulmerton RdCLEARWATER, FL, United States 33760-4004
- Phone
- 727-384-2323
- Fax
- 631-421-5821
Executives
- Independent Chairman of the Board
- Andrew Makrides
- Chief Executive Officer, Director
- Charles Goodwin
- Independent Vice Chairman of the Board
- John Andres
- Chief Financial Officer
- Matthew Hill
- Executive Vice President
- Todd Hornsby
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $52.0M |
|---|---|
Revenue (TTM) | $52.3M |
Shares Outstanding | 34.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.09 |
EPS | $-0.54 |
Book Value | $0.77 |
P/E Ratio | -2.7x |
Price/Sales (TTM) | 1.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -38.87% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
